RAPT RAPT Therapeutics

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at .

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.

RAPT Investor Contact:

Sylvia Wheeler

RAPT Media Contact:

Aljanae Reynolds



EN
09/01/2025

Underlying

RAPTRAPT Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPT Therapeutics

 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare...

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacifi...

January 9, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Boa...

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consulta...

January 6, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Announces $150 Million Private Placement

RAPT Therapeutics Announces $150 Million Private Placement SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain i...

December 23, 2024 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclu...

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN F...

December 23, 2024 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024. Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 Third Quarter Ended Septemb...

November 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch